Trial Profile
Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus Erythematosus; a Phase Ib Clinical Trial and Associated Mechanistic Studies
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Tofacitinib (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions
- 27 Apr 2018 Status changed from recruiting to completed.
- 22 Jun 2016 Status changed from not yet recruiting to recruiting.
- 16 Jun 2016 Status changed from recruiting to not yet recruiting.